Nasogastric tube induced refractory epistaxis during liver transplantation

Yun Hee Kim, Byung Gun Lim, Yong Sang Yoon, Soon Young Hong, Yoon Sook Lee, Woon Young Kim, Jung Hyun Don

Abstract


Cirrhosis has many possible manifestations. These signs and symptoms may be either the direct results of liver cell failure or secondary to the resultant portal hypertension. Portal hypertension can decrease the number of platelets, which increases the risk of bleeding.  Additionally, the liver plays a central role in hemostasis, because it is the site of clotting factors synthesis, coagulation inhibitors, and fibrinolytic proteins. Low platelet count and prolonged clotting times may increase the risk of epistaxis arising from minimal trauma, which can cause sometimes serious and occasionally fatal results. We experienced an intraoperative refractory epistaxis in a 60-year-old man with end-stage liver disease (ESLD) due to hepatitis B virus-related hepatocellular carcinoma during liver transplantation. The patient started severe epistaxis after we attempted to place a nasogastric (NG) tube. We describe successful management of massive epistaxis in an operating room under appropriate anesthesia and close hemodynamic monitoring.

 

Keywords: End-stage liver disease; Epistaxis; Liver transplantation; Nasogastric tube


Full Text:

PDF

References


Tripodi A, Mannucci PM. The Coagulopathy of Chronic Liver Disease. New England Journal of Medicine. 2011;365:147-56.

Camus M, Jensen DM, Matthews JD, Ohning GV, Kovacs TO, Jutabha R, et al. Epistaxis in end stage liver disease masquerading as severe upper gastrointestinal hemorrhage. World Journal of Gastroenterology : WJG 2014;20:13993-8.

Koh E, Frazzini VI, Kagetsu NJ. Epistaxis: vascular anatomy, origins, and endovascular treatment. AJR Am J Roentgenol. 2000;174:845-51.

Gifford TO, Orlandi RR. Epistaxis. Otolaryngol Clin North Am. 2008;41:525-36.

Blonski W, Siropaides T, Reddy KR. Coagulopathy in liver disease. Curr Treat Options Gastroenterol. 2007;10:464-73.

Viehweg TL, Roberson JB, Hudson JW. Epistaxis: diagnosis and treatment. J Oral Maxillofac Surg. 2006;64:511-8.

Douglas R, Wormald PJ. Update on epistaxis. Curr Opin Otolaryngol Head Neck Surg. 2007;15:180-3.

Katz RI, Hovagim AR, Finkelstein HS, Grinberg Y, Boccio RV, Poppers PJ. A comparison of cocaine, lidocaine with epinephrine, and oxymetazoline for prevention of epistaxis on nasotracheal intubation. J Clin Anesth. 1990;2:16-20.

Groudine SB, Hollinger I, Jones J, DeBouno BA. New York State guidelines on the topical use of phenylephrine in the operating room. The Phenylephrine Advisory Committee. Anesthesiology. 2000;92:859-64.

Krempl GA, Noorily AD. Use of Oxymetazoline in the Management of Epistaxis. Annals of Otology, Rhinology & Laryngology. 1995;104:704-6.

Paul J, Kanotra SP, Kanotra S. Endoscopic Management of Posterior Epistaxis. Indian Journal of Otolaryngology and Head & Neck Surgery. 2011;63:141-4.

Garcovich M, Burroughs AK, Campanale C, Gasbarrini A. Monitoring of haemostasis during liver transplantation. Open Transplantation Journal. 2011;5:56-62.


Refbacks

  • There are currently no refbacks.




Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

2013-2019 (CC-BY) Australian International Academic Centre PTY.LTD.

Advances in Bioscience and Clinical Medicine